Reason for request
Re-assessment of the actual benefit (AB) and the level of improvement in actual benefit (IAB) at the request of the applicant.
Clinical Benefit
| Low |
The actual benefit of MYOZYME remains low in the treatment of late-onset Pompe disease. |
Clinical Added Value
| minor |
The improvement in actual benefit remains minor (level IV) in the treatment of late-onset Pompe disease. |
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
MAjUkksy2jW0TFDe
